640 related articles for article (PubMed ID: 1352024)
21. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
22. Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Cleri LB; Kris MG; Tyson LB; Pisters KM; Clark RA; Gralla RJ
Cancer; 1995 Sep; 76(5):774-8. PubMed ID: 8625179
[TBL] [Abstract][Full Text] [Related]
23. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.
Ann Oncol; 1995 Oct; 6(8):805-10. PubMed ID: 8589019
[TBL] [Abstract][Full Text] [Related]
24. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Ballatori E; Roila F; Berto P; De Angelis V; Neri C; Olivieri A; Tonato M; Del Favero A
Pharmacoeconomics; 1994 Mar; 5(3):227-37. PubMed ID: 10146897
[TBL] [Abstract][Full Text] [Related]
25. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.
Kris MG; Gralla RJ; Tyson LB; Clark RA; Kelsen DP; Reilly LK; Groshen S; Bosl GJ; Kalman LA
Cancer; 1985 Feb; 55(3):527-34. PubMed ID: 3880660
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
[TBL] [Abstract][Full Text] [Related]
27. Combination antiemetics for cisplatin chemotherapy.
Sridhar KS; Donnelly E
Cancer; 1988 Apr; 61(8):1508-17. PubMed ID: 3280112
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Ann Oncol; 1994 Sep; 5(7):585-9. PubMed ID: 7993832
[TBL] [Abstract][Full Text] [Related]
29. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Roila F; Ruggeri B; Ballatori E; Fatigoni S; Caserta C; Licitra L; Mirabile A; Ionta MT; Massidda B; Cavanna L; Palladino MA; Tocci A; Fava S; Colantonio I; Angelelli L; Ciuffreda L; Fasola G; Zerilli F
Ann Oncol; 2015 Jun; 26(6):1248-1253. PubMed ID: 25743855
[TBL] [Abstract][Full Text] [Related]
30. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
Kris MG; Gralla RJ; Clark RA; Tyson LB; Fiore JJ; Kelsen DP; Groshen S
Cancer Treat Rep; 1985 Nov; 69(11):1257-62. PubMed ID: 3912039
[TBL] [Abstract][Full Text] [Related]
31. Ondansetron: a review of its use as an antiemetic in children.
Culy CR; Bhana N; Plosker GL
Paediatr Drugs; 2001; 3(6):441-79. PubMed ID: 11437189
[TBL] [Abstract][Full Text] [Related]
32. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
Tonato M
Eur J Cancer; 1991; 27 Suppl 1():S12-4; discussion S22. PubMed ID: 1831628
[TBL] [Abstract][Full Text] [Related]
33. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
34. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
[TBL] [Abstract][Full Text] [Related]
35. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.
Cunningham D; Dicato M; Verweij J; Crombez R; de Mulder P; du Bois A; Stewart A; Smyth J; Selby P; van Straelen D; Parideans R; McQuade B; McRae J
Ann Oncol; 1996 Mar; 7(3):277-82. PubMed ID: 8740792
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
Köseoglu V; Kürekçi AE; Sarici U; Atay AA; Ozcan O
Eur J Pediatr; 1998 Oct; 157(10):806-10. PubMed ID: 9809818
[TBL] [Abstract][Full Text] [Related]
37. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Gebbia V; Testa A; Cannata G; Gebbia N
Anticancer Drugs; 1996 Sep; 7(7):734-7. PubMed ID: 8949983
[TBL] [Abstract][Full Text] [Related]
38. The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial.
Chua DT; Sham JS; Au GK; Choy D; Kwong DL; Yau CC; Cheng AC
Br J Clin Pharmacol; 1996 May; 41(5):403-8. PubMed ID: 8735681
[TBL] [Abstract][Full Text] [Related]
39. Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.
Hesketh PJ
Semin Oncol; 1992 Aug; 19(4 Suppl 10):33-40. PubMed ID: 1387248
[TBL] [Abstract][Full Text] [Related]
40. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
